Galderma Group
CHF 160.55Change from previous close: −0.16%Absolute change: −CHF 0.25
At a glance
- Revenue growth
- +18.04%
- 2025 vs 2024
- Net income growth
- +165.37%
- 2025 vs 2024
- Net margin
- 11.7%
- 2024: 5.2%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 5,241 | 4,440 | 4,117 | 3,824 | 3,445 |
| Cost of revenue | 1,632 | 1,355 | 1,232 | 1,194 | 1,034 |
| Gross profit | 3,609 | 3,085 | 2,885 | 2,630 | 2,411 |
| Selling, general and administrative | 2,490 | 2,151 | 1,990 | 1,908 | 1,711 |
| Research and development | 245 | 260 | 287 | 316 | 343 |
| Operating income | 885 | 671 | 606 | 401 | 350 |
| EBIT | 885 | 671 | 606 | 401 | 350 |
| EBITDA | 1,134 | 891 | 818 | 630 | 567 |
| Interest expense | 173 | 352 | 561 | 398 | 353 |
| Pre-tax income | 639 | 310 | 11.0 | -51.9 | -79.6 |
| Income tax | 26.0 | 79.0 | 68.0 | 45.0 | 4.6 |
| Net income | 613 | 231 | -57.0 | -98.5 | -154 |
| Net income to common shareholders | 613 | 231 | -57.0 | -98.5 | -154 |
| Basic EPS | 2.60 | 0.97 | -0.24 | -0.02 | -0.03 |
| Diluted EPS | 2.58 | 0.97 | -0.24 | -0.02 | -0.03 |
| Average shares (basic) | 236 | 238 | 238 | 5,188 | 5,188 |
| Average shares (diluted) | 237 | 238 | 238 | 5,188 | 5,188 |
| Dividend per share | 0.44 | 0.17 | — | — | — |